Adenosine A1 receptor antag 
Welcome,         Profile    Billing    Logout  
 7 Companies  7 Products   7 Products   6 Diseases   28 Trials   256 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PBF-680 / Palobiofarma
2021-001732-25: A clinical trial to assess the effect of PBF-680 in patients with moderate to severe Chronic Obstructive Pulmonar Disease on top of standard medication. Ensayo clínico para evaluar el efecto del PBF-680 en pacientes con Enfermedad Pulmonar Obstructiva Crónica de moderada a severa, conjuntamente con la medicación habitual.

Ongoing
2
102
Europe
PBF-680, Capsule, hard
Palobiofarma, S.L, Palobiofarma, S.L
Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Respire, NCT05262218: Therapeutic Effect of PBF-680 in Patients With COPD

Completed
2
174
Europe
PBF-680 10mg, Placebo
Palobiofarma SL, Scope International AG
COPD
02/24
04/24
Peyona (caffeine citrate) / Chiesi
2015-003274-32: Effect of caffeine citrate in acute bronchiolitis symptoms of apnea in neonates and infants during the first three months of life Efecto del citrato de cafeína en las bronquiolitis agudas con sintomatología de apnea en neonatos y lactantes durante los primeros tres meses de vida

Ongoing
3
96
Europe
Solution for infusion, Peyona
Dra Maria Luz Couce, Dr. José Luis Fernández Trisac, Chiesi Farmaceutici S.p.A., CHIESI
Children under 3 years with acute RSV bronchiolitis which present breaks apnea Niños menores de 3 años con bronquiolitis aguda por VRS que presentan pausas de apnea, Children under 3 years with a respiratory infection caused by respiratory syncytial virus and having pauses in breathing Niños menores de 3 años con una infección respiratoria causada por el virus respiratorio sincitial y que presentan pausas en la respiración, Not possible to specify
 
 
2018-003626-91: CAFFEINE TREATMENT IN DELIVERY ROOM FOR VERY PRETERM INFANTS : A FEASIBILITY STUDY TRATTAMENTO DEL NEONATO MOLTO PRETERMINE CON CAFFEINA IN SALA PARTO: STUDIO DI FATTIBILITA’

Ongoing
2
40
Europe
Peyona, [40889014], Solution for injection, PEYONA - 20MG/ML - SOLUZIONE PER INFUSIONE E SOLUZIONE ORALE - PER SOMMINISTRAZIONE ENDOVENOSA E ORALE - FLACONCINO(VETRO) 10 FLACONCINI DA 3 ML
AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
25+0-29+6 gestational age preterm infants at risk of respiratory distress syndrome with no need of mechanical ventilation in delivery room. Neonati di età gestazionale pari a 25+0-29+6 settimane ad alto rischio di sviluppare “respiratory distress syndrome” (RDS) che non richiedano ventilazione meccanica in sala parto., 25+0-29+6 gestational age preterm infants with no need of mechanical ventilation in delivery room. Neonati di età gestazionale pari a 25+0-29+6 settimane ad alto rischio di insufficienza respiratoria che non richiedano ventilazione meccanica in sala parto., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
caffeine/naproxen (BAY2880376) / Bayer
NCT05485805 / 2022-003274-22: A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo

Completed
3
541
US
Naproxen sodium and caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Bayer
Postoperative Dental Pain
01/24
01/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PBF-680 / Palobiofarma
2021-001732-25: A clinical trial to assess the effect of PBF-680 in patients with moderate to severe Chronic Obstructive Pulmonar Disease on top of standard medication. Ensayo clínico para evaluar el efecto del PBF-680 en pacientes con Enfermedad Pulmonar Obstructiva Crónica de moderada a severa, conjuntamente con la medicación habitual.

Ongoing
2
102
Europe
PBF-680, Capsule, hard
Palobiofarma, S.L, Palobiofarma, S.L
Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Respire, NCT05262218: Therapeutic Effect of PBF-680 in Patients With COPD

Completed
2
174
Europe
PBF-680 10mg, Placebo
Palobiofarma SL, Scope International AG
COPD
02/24
04/24
Peyona (caffeine citrate) / Chiesi
2015-003274-32: Effect of caffeine citrate in acute bronchiolitis symptoms of apnea in neonates and infants during the first three months of life Efecto del citrato de cafeína en las bronquiolitis agudas con sintomatología de apnea en neonatos y lactantes durante los primeros tres meses de vida

Ongoing
3
96
Europe
Solution for infusion, Peyona
Dra Maria Luz Couce, Dr. José Luis Fernández Trisac, Chiesi Farmaceutici S.p.A., CHIESI
Children under 3 years with acute RSV bronchiolitis which present breaks apnea Niños menores de 3 años con bronquiolitis aguda por VRS que presentan pausas de apnea, Children under 3 years with a respiratory infection caused by respiratory syncytial virus and having pauses in breathing Niños menores de 3 años con una infección respiratoria causada por el virus respiratorio sincitial y que presentan pausas en la respiración, Not possible to specify
 
 
2018-003626-91: CAFFEINE TREATMENT IN DELIVERY ROOM FOR VERY PRETERM INFANTS : A FEASIBILITY STUDY TRATTAMENTO DEL NEONATO MOLTO PRETERMINE CON CAFFEINA IN SALA PARTO: STUDIO DI FATTIBILITA’

Ongoing
2
40
Europe
Peyona, [40889014], Solution for injection, PEYONA - 20MG/ML - SOLUZIONE PER INFUSIONE E SOLUZIONE ORALE - PER SOMMINISTRAZIONE ENDOVENOSA E ORALE - FLACONCINO(VETRO) 10 FLACONCINI DA 3 ML
AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
25+0-29+6 gestational age preterm infants at risk of respiratory distress syndrome with no need of mechanical ventilation in delivery room. Neonati di età gestazionale pari a 25+0-29+6 settimane ad alto rischio di sviluppare “respiratory distress syndrome” (RDS) che non richiedano ventilazione meccanica in sala parto., 25+0-29+6 gestational age preterm infants with no need of mechanical ventilation in delivery room. Neonati di età gestazionale pari a 25+0-29+6 settimane ad alto rischio di insufficienza respiratoria che non richiedano ventilazione meccanica in sala parto., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
caffeine/naproxen (BAY2880376) / Bayer
NCT05485805 / 2022-003274-22: A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo

Completed
3
541
US
Naproxen sodium and caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Bayer
Postoperative Dental Pain
01/24
01/24

Download Options